zioptan

TO MARK MCGOWAN, the RATBAG premier of Western Australia and to all glaucoma sufferers throughout Australia.

ZIOPTAN or Tafluprost is a flourinated analogue of prostaglandin F2a . The chemical name for tafluprost is 1 methylethyl 5Z – 7 ((1R,2R,3R,5S) -2- ((1E) -3,3-difluoro -4- phenoxy-1-butenyl) – 3,5- dihydroxycyclopentyl ) -5- heptenoate. The molecular formula of tafluprost is C25H34F2O5 and its molecular weight is 452 .53. Tafluprost is a colorless to light yellow viscous liquid that is practically insoluble in water.

ZIOPTAN or Tafluprost is also a prostaglandin analogue. It is used topically to control the progression of open angle glaucoma and in the management of ocular hypertension. It reduces intraocular pressure by increasing the outflow of aqueous fluid from the eyes.

Tafluprost is a prodrug of the active substance, tafluprost acid a structural and functional analogue of prostaglandin F2a (PGF 2a). Tafluprost acid is a selective agonist at the prostaglandin F receptor, increasing outflow of aqueous fluid from the eyes and thus lowering intraocular pressure.

Other PGF 2a analogues with the same mechanism include latanaprost and travoprost.

Tafluprost, as a lipophilic ester, easily penetrates the cornea and is then activated to the carboxylic acid, tafluprost acid. Onset of action is 2 – 4 hours after application the maximal effect is reached after 12 hours and ocular pressure remains lowered for at least 24 hours.

Tafluprost acid is inactivated by beta oxidation to 1,2 dinortafluprost acid, 1,2,3,4 tetranortafluprost acid and its lactone which are subsequently glucuronidated or hydroxylated. The cytochrome P450 liver enzyme play no role in the metabolism.

An analogue pathway has been found for latanaprost and travoprost.

The recommended dose of ZIOPTAN is 1 drop of ZIOPTAN in the conjunctival sac of the affected eye once daily. The dose should not exceed once daily since it has been shown that more frequent applications of prostaglandin analogs may lessen the intraocular pressure lowering effects.

On 17 February 2012, ZIOPTAN, the first preservative free prostaglandin ophthalmic solution eye drop medication used to treat glaucoma was approved by the U.S. Food and Drug Administration. The new preservative free glaucoma medication known as ZIOPTAN is distributed by Merck ( NYSE: MRK ). It gained approval in 2012 and is still not available in this backward State of Western Australia led by a backward Premier called Mark McGowan.

I would urge all glaucoma sufferers throughout the world to email Mark McGowan at: wa-government@dpc.wa.gov.au

and tell him what a fool he is and urge him to make ZIOPTAN available to all the glaucoma sufferers throughout the State of Western Australia or better still urge him to make TAPCOM available instead of ZIOPTAN.

TAPCOM is a prescription pharmaceutical made by Santen and Asahi Glass Co. Ltd. (Tokyo) and contains both tafluprost and timolol maleate.

SOURCES:

https://sites.google.com/view/keratoconus

https://sites.google.com/view/markmcgowan

https://sites.google.com/view/royalperthhospital

https://sites.google.com/view/lionseyeinstituteofwa

https://sites.google.com/view/haigis

https://sites.google.com/view/cystoidmacularedema

https://sites.google.com/view/cataractoperation

https://sites.google.com/view/xengelstent

https://sites.google.com/view/dryeye

https://sites.google.com/view/xen45